Rachel Kobos

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Renier J. Brentjens, Marco L. Davila, Isabelle Rivière et al. · Science Translational Medicine · 2013 · 2.1K citations · Full text

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 990 citations · Full text

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 947 citations · Full text

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 430 citations · Full text

Hematological Malignancy, Overall Survival, Medicine +7

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Kevin J. Curran, Steven Margossian, Nancy A. Kernan et al. · Blood · 2019 · 272 citations · Full text

Cell Therapy, Mixed-phenotype Acute Leukemia, Immunology +18